phrykt

BridgeBio Pharma, Inc. (BBIO): who owns it and who trades it

As of Nov 16, 2026, BBIO insiders reported 130 open-market sales worth $90.8M and no purchases in the last 12 months, with 93% of the sale value made under pre-set 10b5-1 plans. The largest seller was Neil Kumar (CEO), with $48.5M. 7 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling BridgeBio Pharma

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Congress mostly bought. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BBIO

473 funds and institutions reported BBIO shares worth $14.5B at the end of Q2 2026, about 100% of the company. The largest holder is Jupiter Topco LLC with 7.2%.

Funds and institutions (13F) 100%Everyone else 0%

10 largest owners, by share of the company

Jupiter Topco LLC7.2%
Kohlberg Kravis Roberts & Co. L.P.6.8%
Farallon Capital Management, L.l.c.5.5%
BlackRock, Inc.5.3%
Viking Global Investors LP5.1%
Vanguard Capital Management LLC4.0%
Vanguard Portfolio Management LLC3.9%
Wellington Management Group LLP2.7%
Two Sigma Investments, LP2.4%
Aisling Capital Management LP2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jupiter Topco LLC14.11M7.20%$1.1B–
Kohlberg Kravis Roberts & Co. L.P.13.26M6.77%$988MNo change
Farallon Capital Management, L.l.c.10.74M5.49%$800M+15%
BlackRock, Inc.10.29M5.25%$766M-28%
Viking Global Investors LP9.95M5.08%$741M-16%
Vanguard Capital Management LLC7.90M4.03%$588M+2%
Vanguard Portfolio Management LLC7.66M3.91%$570M-5%
Wellington Management Group LLP5.31M2.71%$395M+114%
Two Sigma Investments, LP4.72M2.41%$352M+51%
Aisling Capital Management LP4.59M2.34%$342M-10%
State Street Corp4.44M2.26%$330M-10%
Citadel Advisors LLC3.76M1.92%$280M+18%
Invesco Ltd.3.70M1.89%$276M-19%
D. E. Shaw & Co., Inc.3.63M1.85%$271M+43%
Geode Capital Management, LLC3.42M1.75%$255M-30%
Jane Street Group, LLC2.93M1.50%$219M+67%
JPMorgan Chase & Co2.40M1.22%$173M–
Adage Capital Partners Gp, L.l.c.2.25M1.15%$168M+276%
Franklin Resources Inc2.16M1.10%$161M-11%
Polar Capital Holdings Plc2.06M1.05%$154M-18%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BBIO insiders reported $0 of open-market purchases and $90.8M of sales. 93% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$90.8M
130 trades, 8 people
Sales under a 10b5-1 plan
93%
Share of sale value
Latest trade
Oct 30, 2026
Filed Nov 3, 2026

Purchases and sales by month

$14.8M$14.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 30, 2026Maricel ApuliChief Accounting OfficerSale plan2,000$72.85$146KForm 4
Sep 17, 2026Neil KumarCEOSale plan1,279$69.57$89KForm 4
Sep 17, 2026Neil KumarCEOSale plan8,721$69.01$602KForm 4
Aug 19, 2026Neil KumarCEOSale plan100$85.65$8.6KForm 4
Aug 19, 2026Neil KumarCEOSale plan1,800$84.69$152KForm 4
Aug 19, 2026Neil KumarCEOSale plan8,100$83.86$679KForm 4
Aug 18, 2026Neil KumarCEOSale plan14,602$82.99$1.2MForm 4
Aug 18, 2026Neil KumarCEOSale plan1,900$81.15$154KForm 4
Aug 18, 2026Neil KumarCEOSale plan17,279$82.21$1.4MForm 4
Aug 18, 2026Neil KumarCEOSale plan1,199$83.77$100KForm 4
Jul 30, 2026Maricel ApuliChief Accounting OfficerSale plan2,000$80.06$160KForm 4
Jul 9, 2026Andrea EllisDirectorSale plan17,167$84.00$1.4MForm 4
Jul 9, 2026Jennifer E. CookDirectorSale plan36,167$84.00$3MForm 4
Jul 9, 2026Jennifer E. CookDirectorSale plan112,422$90.00$10.1MForm 4
Jun 24, 2026Jennifer E. CookDirectorSale plan37,167$70.00$2.6MForm 4
Jun 23, 2026Jennifer E. CookDirectorSale plan2,196$68.57$151KForm 4
Jun 22, 2026Hannah ValantineDirectorSale plan2,808$68.00$191KForm 4
Jun 15, 2026Jennifer E. CookDirectorSale plan1,503$67.14$101KForm 4
Jun 15, 2026Jennifer E. CookDirectorSale plan88,737$66.62$5.9MForm 4
Jun 5, 2026Neil KumarCEOSale plan7,147$67.20$480KForm 4
Jun 5, 2026Neil KumarCEOSale plan4,415$68.96$304KForm 4
Jun 5, 2026Neil KumarCEOSale plan4,416$68.96$305KForm 4
Jun 5, 2026Neil KumarCEOSale plan8,437$67.88$573KForm 4
Jun 5, 2026Neil KumarCEOSale plan7,148$67.20$480KForm 4
Jun 4, 2026Neil KumarCEOSale plan2,200$65.72$145KForm 4
Jun 4, 2026Neil KumarCEOSale plan1,429$66.72$95.3KForm 4
Jun 4, 2026Neil KumarCEOSale plan15,921$67.74$1.1MForm 4
Jun 4, 2026Neil KumarCEOSale plan450$68.27$30.7KForm 4
May 21, 2026Neil KumarCEOSale plan800$70.92$56.7KForm 4
May 21, 2026Neil KumarCEOSale plan2,256$67.57$152KForm 4
May 21, 2026Neil KumarCEOSale plan6,725$68.30$459KForm 4
May 21, 2026Neil KumarCEOSale plan5,072$69.22$351KForm 4
May 21, 2026Neil KumarCEOSale plan11,250$70.48$793KForm 4
May 18, 2026Thomas TrimarchiCFOSale plan10,456$64.82$678KForm 4
May 18, 2026Thomas TrimarchiCFOSale plan3,195$65.95$211KForm 4
May 15, 2026Randal W. ScottDirectorSale plan200$69.12$13.8KForm 4
May 15, 2026Randal W. ScottDirectorSale plan2,088$67.53$141KForm 4
May 15, 2026Randal W. ScottDirectorSale plan1,512$68.23$103KForm 4
May 15, 2026Randal W. ScottDirectorSale plan6,200$66.69$413KForm 4
May 8, 2026Neil KumarCEOSale plan13,973$66.65$931KForm 4
May 8, 2026Neil KumarCEOSale plan5,077$67.35$342KForm 4
May 8, 2026Neil KumarCEOSale plan950$68.35$64.9KForm 4
May 8, 2026Neil KumarCEOSale plan13,974$66.65$931KForm 4
May 8, 2026Neil KumarCEOSale plan5,076$67.35$342KForm 4
May 7, 2026Neil KumarCEOSale plan8,333$68.38$570KForm 4
May 7, 2026Neil KumarCEOSale plan450$69.09$31.1KForm 4
May 7, 2026Neil KumarCEOSale plan11,217$67.49$757KForm 4
May 7, 2026Neil KumarCEOSale plan8,334$68.38$570KForm 4
May 7, 2026Neil KumarCEOSale plan11,217$67.50$757KForm 4
May 7, 2026Neil KumarCEOSale plan449$69.09$31KForm 4
Apr 30, 2026Maricel ApuliChief Accounting OfficerSale plan2,000$71.58$143KForm 4
Apr 10, 2026Neil KumarCEOSale plan20,000$74.60$1.5MForm 4
Apr 9, 2026Neil KumarCEOSale plan7,200$73.64$530KForm 4
Apr 9, 2026Neil KumarCEOSale plan7,800$75.53$589KForm 4
Apr 9, 2026Neil KumarCEOSale plan5,128$74.57$382KForm 4
Apr 9, 2026Neil KumarCEOSale plan7,072$73.64$521KForm 4
Apr 9, 2026Neil KumarCEOSale plan7,500$75.55$567KForm 4
Apr 9, 2026Neil KumarCEOSale plan5,300$74.60$395KForm 4
Mar 13, 2026Neil KumarCEOSale plan9,759$69.23$676KForm 4
Mar 13, 2026Neil KumarCEOSale plan9,690$68.36$662KForm 4
Mar 13, 2026Neil KumarCEOSale plan10,310$69.20$713KForm 4
Mar 13, 2026Neil KumarCEOSale plan10,241$68.39$700KForm 4
Mar 12, 2026Neil KumarCEOSale plan300$70.15$21KForm 4
Mar 12, 2026Neil KumarCEOSale plan5,815$69.29$403KForm 4
Mar 12, 2026Neil KumarCEOSale plan5,363$69.32$372KForm 4
Mar 12, 2026Neil KumarCEOSale plan14,337$68.48$982KForm 4
Mar 12, 2026Neil KumarCEOSale plan13,885$68.47$951KForm 4
Mar 10, 2026Hannah ValantineDirectorSale plan8,671$72.00$624KForm 4
Mar 4, 2026Andrea EllisDirectorSale plan64,921$64.87$4.2MForm 4
Feb 27, 2026Hannah ValantineDirectorSale plan10,900$67.84$739KForm 4
Feb 27, 2026Hannah ValantineDirectorSale plan14,584$67.08$978KForm 4
Feb 26, 2026Maricel ApuliChief Accounting OfficerSale plan2,000$66.00$132KForm 4
Feb 19, 2026Neil KumarCEOSale plan18,923$71.03$1.3MForm 4
Feb 19, 2026Neil KumarCEOSale plan8,528$72.08$615KForm 4
Feb 19, 2026Neil KumarCEOSale plan602$72.80$43.8KForm 4
Feb 17, 2026Maricel ApuliChief Accounting OfficerSale plan510$74.31$37.9KForm 4
Feb 17, 2026Thomas TrimarchiCFOSale plan200$75.38$15.1KForm 4
Feb 17, 2026Thomas TrimarchiCFOSale plan13,400$74.71$1MForm 4
Feb 17, 2026Randal W. ScottDirectorSale plan1,900$74.34$141KForm 4
Feb 17, 2026Randal W. ScottDirectorSale plan4,793$75.57$362KForm 4
Feb 17, 2026Randal W. ScottDirectorSale plan3,307$75.93$251KForm 4
Feb 11, 2026Neil KumarCEOSale plan7,860$70.70$556KForm 4
Feb 11, 2026Neil KumarCEOSale plan3,994$73.25$293KForm 4
Feb 11, 2026Neil KumarCEOSale plan3,961$73.25$290KForm 4
Feb 11, 2026Neil KumarCEOSale plan4,404$72.65$320KForm 4
Feb 11, 2026Neil KumarCEOSale plan3,775$71.46$270KForm 4
Feb 11, 2026Neil KumarCEOSale plan4,484$72.64$326KForm 4
Feb 11, 2026Neil KumarCEOSale plan7,806$70.69$552KForm 4
Feb 11, 2026Neil KumarCEOSale plan3,716$71.44$265KForm 4
Feb 10, 2026Neil KumarCEOSale plan5,799$72.28$419KForm 4
Feb 10, 2026Neil KumarCEOSale plan14,040$71.80$1MForm 4
Feb 10, 2026Neil KumarCEOSale plan5,960$72.27$431KForm 4
Feb 10, 2026Neil KumarCEOSale plan14,201$71.80$1MForm 4
Jan 9, 2026Neil KumarCEOSale plan2,151$75.75$163KForm 4
Jan 9, 2026Neil KumarCEOSale plan1,855$78.10$145KForm 4
Jan 9, 2026Neil KumarCEOSale plan10,677$77.46$827KForm 4
Jan 9, 2026Neil KumarCEOSale plan6,067$76.53$464KForm 4
Jan 9, 2026Neil KumarCEOSale plan1,401$75.61$106KForm 4
Jan 9, 2026Neil KumarCEOSale plan375$78.19$29.3KForm 4
Jan 9, 2026Neil KumarCEOSale plan10,519$77.61$816KForm 4

Latest 100 of 130 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Neil KumarChief Executive Officer, Director–$48.5MSep 17, 2026
Jennifer E. CookDirector–$21.9MJul 9, 2026
Andrew LoDirector–$6.3MNov 18, 2025
Andrea EllisDirector–$5.7MJul 9, 2026
Thomas TrimarchiPresident and CFO–$3MMay 18, 2026
Hannah ValantineDirector–$2.5MJun 22, 2026
Randal W. ScottDirector–$2.1MMay 15, 2026
Maricel ApuliChief Accounting Officer–$767KOct 30, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BBIO short interest

High short interest. 10.7% of BBIO shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 14%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 20.85M BBIO shares were sold short, 10.7% of the shares outstanding, up 4.2% from the report before. At the average daily volume of 2.95M shares, buying them all back would take about 7.1 trading days (days to cover).

Shares short, % of all shares

10.7%May 15Oct 3013.6%

Days to cover

7.1May 15Oct 3012.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202620.85M10.70%+4%2.95M7.1
Oct 15, 202620.00M10.23%+2%2.60M7.7
Sep 30, 202619.67M10.06%-9%3.36M5.8
Sep 15, 202621.55M11.02%-1%2.04M10.5
Aug 31, 202621.85M11.18%-6%1.95M11.2
Aug 14, 202623.32M11.93%-0%2.16M10.8
Jul 31, 202623.34M11.92%-9%2.03M11.5
Jul 15, 202625.75M13.15%+7%4.79M5.4
Jun 30, 202624.10M12.31%-5%5.34M4.5
Jun 15, 202625.42M12.98%+4%2.97M8.6
May 29, 202624.39M12.45%+1%2.54M9.6
May 15, 202624.16M12.34%+1%2.77M8.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded BBIO

Since Nov 17, 2024, 1 member of Congress reported 9 purchases and 1 sale of BBIO. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Nov 2, 2026, reported Nov 10, 2026.

Purchases 9Sales 1

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Nov 2, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfNov 10, 2026Report
Oct 27, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfNov 10, 2026Report
Sep 29, 2026Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfOct 12, 2026Report
May 11, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfJun 8, 2026Report
Apr 29, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfMay 8, 2026Report
Mar 19, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Mar 18, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Mar 3, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Sep 22, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfOct 10, 2025Report
Aug 8, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfSep 12, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

BridgeBio Pharma company events

BridgeBio Pharma filed 17 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Oct 13, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by… Filing
  3. Aug 31, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled, “BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein… Filing
  4. Aug 17, 2026AgreementBridgeBio Pharma, Inc. and KKR Genetic Disorder L.P. entered into an Underwriting Agreement with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC, as the representatives of the several underwriters listed on Schedule I thereto, related to an offering of 5,000,000… Filing
  5. Aug 10, 2026ResultsReleased financial results. Filing
  6. Jul 22, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
  7. Jul 2, 2026AgreementBridgeBio Pharma, Inc. entered into an Investment Agreement with the purchasers identified therein, including Chinotto Investments, LLC and HCRx Investments HoldCo, L.P., providing for the issuance and sale by the Company to the Purchasers of shares of the Company’s Series A Cumulative Convertible… Filing
  8. Jun 26, 2026LeadershipDr. Randal W. Scott notified BridgeBio Pharma, Inc., of his resignation as a member of the Board of Directors of the Company upon the completion of his term as a Class I director, effective as of June 22, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders. Filing
  9. May 27, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
  10. May 13, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
  11. May 8, 2026AgreementBridgeBio Pharma, Inc. filed a registration statement on Form S-3ASR (File No.: 333-295678, the “Registration Statement”) under Rule 415 of the Securities Act of 1933, as amended with the Securities and Exchange Commission . In addition, on May 7, 2026, the Company entered into an Equity… Filing
  12. May 7, 2026AnnouncementThe Board of Directors of the Company approved a stock repurchase program pursuant to which the Company may purchase up to $500 million of the Company’s outstanding common stock. Filing
  13. Mar 30, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
  14. Feb 24, 2026ResultsReleased financial results. Filing
  15. Feb 12, 2026AnnouncementBridgeBio Pharma, Inc. issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia.” A copy of the press release is attached as Exhibit 99.1 to this Current… Filing
  16. Jan 21, 2026AgreementBridgeBio Pharma, Inc. issued an aggregate of $632.5 million of its 0.75% Convertible Senior Notes due 2033, pursuant to an Indenture dated January 21, 2026, between BridgeBio and U.S. Bank Trust Company, National Association, as trustee, in a private offering to qualified institutional buyers… Filing
  17. Jan 12, 2026AnnouncementThe Company also presented a business update at the 44 th Annual J.P. Morgan Healthcare Conference. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

BridgeBio Pharma financials

Famous investors that hold BBIO

7 of the 50 well-known investors we track reported holding BBIO in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $644M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 20269.79M$644M2.0%-2%
Ken Griffin · Citadel AdvisorsQ3 20261.73M$114M0.1%-54%
Jim Simons · Renaissance TechnologiesQ3 2026856,546$56.4M0.1%No change
Ray Dalio · Bridgewater AssociatesQ3 2026695,638$45.8M0.2%+55%
Israel Englander · Millennium ManagementQ3 2026622,296$40.9M0.0%+28%
Steve Cohen · Point72 Asset ManagementQ3 2026602,374$39.6M0.1%-61%
Ken Fisher · Fisher Asset ManagementQ3 2026348,675$22.9M0.0%+1%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named BBIO in the last 120 days.

FiledHolderFormStake
Nov 12, 2026Farallon Capital Management, L.L.C.13G/A7.3%
Nov 12, 2026Farallon Capital Management, L.L.C.13G/A7.3%
Oct 27, 2026BlackRock, Inc.13G5.1%
Oct 27, 2026BlackRock, Inc.13G5.1%

Questions about BridgeBio Pharma, Inc. (BBIO) stock

Who owns the most BBIO stock?

The largest reported owner of BridgeBio Pharma, Inc. (BBIO) is Jupiter Topco LLC, with 7.2% of the company. In total, 473 funds and institutions reported holding BBIO at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are BBIO insiders buying or selling?

In the last 12 months, BBIO insiders reported no open-market purchases and 130 sales worth $90.8M. The latest trade was on Oct 30, 2026. See every trade.

What is the short interest in BBIO?

As of Oct 30, 2026, 20.85M BBIO shares were sold short, 10.7% of the shares outstanding, up 4.2% from the report before. At the average daily volume of 2.95M shares, buying them all back would take about 7.1 trading days (days to cover). See the history.

Have members of Congress traded BBIO?

Yes. 1 member of Congress reported 9 purchases and 1 sale of BBIO since Nov 17, 2024. The latest was reported on Nov 10, 2026. See the trades.

Which famous investors hold BBIO?

7 of the 50 well-known investors we track reported BBIO in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Jim Simons. The largest position is worth $644M. See all holders.

Executive pay

BridgeBio Pharma's chief executive was paid a total of $14.9M for the year ended Dec 31, 2025, down 4% from $15.6M the year before. In the last 12 months, BridgeBio Pharma's executives and directors bought no stock on the open market and sold $90.8M.

Chief executive, total pay$14.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$75.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.